FOLR2 and neoplasm: A folate-conjugated TLR7 agonist against FRβ-expressing macrophages not only showed in vivo activity in a range of tumor models, including metastatic lesions, but also reversed the expression of a high M2-like to M1-like macrophage ratio and increased the infiltration of cytotoxic CD8 T cells [15].